Welcome to our dedicated page for AC Immune SEC filings (Ticker: ACIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AC Immune SA filings document a foreign private issuer developing precision therapeutics and diagnostics for neurodegenerative diseases. Recent Form 6-K reports furnish press releases, IFRS financial statements, management discussion and annual statutory and compensation reports, with certain reports incorporated by reference into Form F-3 and Form S-8 registration statements.
The disclosures cover clinical and trial updates for ACI-24, ACI-7104.056, ACI-19764 and ACI-35.030/JNJ-2056; collaboration amendments for Morphomer® Tau small molecules; cash resources and operating requirements; and governance-related compensation reporting. They also record exhibit-based material updates for AC Immune’s active immunotherapy, small-molecule and diagnostic pipeline.
AC Immune SA Chief Executive Officer Andrea Pfeifer reported an open-market sale of 10,000 common shares. The trade occurred on May 15, 2026 at a weighted average price of $2.7935 per share, with individual prices ranging from $2.75 to $2.825.
After this sale, Pfeifer directly holds 3,820,288 common shares, which include 1,921,005 common shares underlying outstanding restricted share units. She also reports 14,000 common shares held indirectly by her spouse.
ACIU affiliate files Form 144 to sell 20,000 common shares. The filing lists 20,000 shares proposed for sale and references prior 10b5-1 sales of 10,000 shares on 02/17/2026, 03/16/2026 and 04/15/2026 with the listed proceeds per sale. The notice identifies the shares as previously exercised stock options.
AC Immune SA has called its 2026 Annual General Meeting for 11 June 2026 and published the invitation and proxy materials. Shareholders will vote on approval of the 2025 IFRS consolidated and statutory financial statements, the 2025 compensation report, loss appropriation, discharge of directors and executives, and binding maximum compensation for the Board and Executive Management.
The Board proposes Board compensation up to CHF 1,029,000 for the term from the 2026 AGM to the 2027 AGM and Executive Management compensation up to CHF 6,742,000 for 2027. Under IFRS, the consolidated net loss for 2025 was CHF 70,447K, with accumulated losses carried forward.
CEO Andrea Pfeifer will retire at the 2026 AGM after 23 years, and Chair Martin Zügel will serve as Interim CEO while remaining Chair. To reinforce governance, the Board appointed Monika Bütler as Lead Independent Director and added Carl June to the Audit & Finance Committee. Shareholders will also vote on introducing a capital band between CHF 2,202,018.50 and CHF 2,862,500.00 and increasing conditional share capital for employee plans to 7,500,000 shares.
AC Immune SA announced that co-founder and long-serving Chief Executive Officer Dr Andrea Pfeifer plans to retire at the Annual General Meeting on June 11, 2026 to spend more time with her family. The company states her decision is not due to any disagreement over operations, policies, or practices.
The Board has appointed its Chair, Dr Martin Zügel, as interim CEO while a search firm leads the process to identify a permanent successor. Dr Pfeifer will remain closely involved as Advisor, Honorary Chair of the Board, and Co-Chair of the Scientific Advisory Board, supporting leadership continuity as AC Immune advances its neurodegenerative disease pipeline and partnerships.
AC Immune SA reported first quarter 2026 results showing it remains a clinical-stage company investing heavily in neurodegenerative disease programs. Contract revenue was CHF 1.1 million, while the Company recorded a net loss of CHF 14.8 million, improving from a CHF 19.0 million loss a year earlier as research and development and general and administrative expenses declined.
As of March 31, 2026, AC Immune held CHF 19.2 million in cash and cash equivalents and CHF 55.6 million in short-term financial assets. The Company states its cash resources are expected to provide sufficient capital to last into Q4 2027, excluding potential milestone payments. Management highlighted progress in collaborations with Takeda and Eli Lilly and pointed to multiple anticipated 2026 clinical milestones across its Alzheimer’s and Parkinson’s disease pipelines.
AC Immune SA reported first quarter 2026 results showing it remains a clinical-stage company investing heavily in neurodegenerative disease programs. Contract revenue was CHF 1.1 million, while the Company recorded a net loss of CHF 14.8 million, improving from a CHF 19.0 million loss a year earlier as research and development and general and administrative expenses declined.
As of March 31, 2026, AC Immune held CHF 19.2 million in cash and cash equivalents and CHF 55.6 million in short-term financial assets. The Company states its cash resources are expected to provide sufficient capital to last into Q4 2027, excluding potential milestone payments. Management highlighted progress in collaborations with Takeda and Eli Lilly and pointed to multiple anticipated 2026 clinical milestones across its Alzheimer’s and Parkinson’s disease pipelines.
AC Immune SA reported that it has dosed the first patients in Cohort AD4, the final planned cohort in its ongoing Phase 1b/2 ABATE trial of ACI-24, an anti-Abeta active immunotherapy for Alzheimer’s disease. Reaching this trial milestone triggers a $12 million payment from partner Takeda under their exclusive, worldwide option and license agreement for active immunotherapies targeting toxic amyloid beta.
The ABATE trial is evaluating ACI-24 in people with prodromal Alzheimer’s disease and adults with Down syndrome. Earlier cohorts AD1–AD3 enrolled 74 patients at escalating doses, with 12‑month data readouts expected later in Q2 2026. AD4 will initially enroll 36 patients treated for 12 months plus 6 months of follow-up, and may be expanded to about 112 subjects, substantially enlarging the safety and biomarker data set for ACI-24.
AC Immune highlights that ACI-24 has so far been generally safe and well tolerated, with anti-Abeta antibody responses observed at all tested doses and no safety concerns raised by multiple data safety monitoring board reviews. Under the Takeda agreement, AC Immune previously received $100 million upfront and remains eligible for an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1 billion, plus tiered double-digit royalties on any worldwide net sales.
AC Immune SA reported that it has dosed the first patients in Cohort AD4, the final planned cohort in its ongoing Phase 1b/2 ABATE trial of ACI-24, an anti-Abeta active immunotherapy for Alzheimer’s disease. Reaching this trial milestone triggers a $12 million payment from partner Takeda under their exclusive, worldwide option and license agreement for active immunotherapies targeting toxic amyloid beta.
The ABATE trial is evaluating ACI-24 in people with prodromal Alzheimer’s disease and adults with Down syndrome. Earlier cohorts AD1–AD3 enrolled 74 patients at escalating doses, with 12‑month data readouts expected later in Q2 2026. AD4 will initially enroll 36 patients treated for 12 months plus 6 months of follow-up, and may be expanded to about 112 subjects, substantially enlarging the safety and biomarker data set for ACI-24.
AC Immune highlights that ACI-24 has so far been generally safe and well tolerated, with anti-Abeta antibody responses observed at all tested doses and no safety concerns raised by multiple data safety monitoring board reviews. Under the Takeda agreement, AC Immune previously received $100 million upfront and remains eligible for an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1 billion, plus tiered double-digit royalties on any worldwide net sales.
AC Immune SA Chief Executive Officer Andrea Pfeifer sold 10,000 shares of the company’s stock in an open-market transaction. The amended filing clarifies that a prior report mistakenly showed this activity as a purchase and now correctly records it as a sale.
The shares were sold at a weighted average price of $3.1425, with individual trade prices ranging from $3.05 to $3.19. After the sale, Pfeifer directly owns 3,830,288 shares, including 1,921,005 common shares underlying outstanding restricted share units, and also has indirect ownership of 14,000 shares held by her spouse.
AC Immune SA Chief Executive Officer Andrea Pfeifer reported an open-market purchase of 10,000 common shares on April 15, 2026 at a weighted average price of $3.1425 per share, with individual trades ranging from $3.05 to $3.19.
Following this transaction, she directly owns 3,830,288 shares, which include 1,921,005 common shares underlying outstanding restricted share units. In addition, 14,000 shares are reported as indirectly owned through her spouse.
Andrea Pfeifer reports intent to sell 10,000 common shares. The Form 144 lists 10,000 shares with an aggregate value of $31,900 and identifies Morgan Stanley Smith Barney LLC as the broker. The filing also records 10b5-1 sales of 10,000 shares on 03/16/2026 for $31,966 and 10,000 shares on 02/17/2026 for $28,693. A 10,000-share block is noted as issuable from previously exercised options dated 06/01/2012.
AC Immune SA has amended its Morphomer® Tau license and collaboration agreement with Eli Lilly and Company to continue joint research and development of Tau aggregation inhibitor small molecules for potential treatment of Alzheimer’s disease and other neurodegenerative diseases.
Under the amendment, AC Immune will receive a CHF 10 million upfront payment and an additional milestone payment upon Phase 1 dosing, alongside previously announced milestones. AC Immune remains eligible for over CHF 1.7 billion in further development, regulatory and commercial milestones, plus tiered low double‑digit royalties on future sales. The company expects to start IND‑enabling studies for new Tau Morphomer candidates imminently.